Senate Passes The COVID-19 3.5 Emergency Relief Bill

Published in Member Communities on April 21, 2020

This afternoon, the Senate passed, by unanimous consent, the $484 billion agreement to deliver more pandemic aid to small businesses and hospitals in addition to federal, state, and local coronavirus testing. The House is expected to return Thursday for an in-person vote.

The measure — originally meant to serve as an “interim” small business fix before lawmakers embarked on negotiations for another trillion-dollar-plus relief package — will provide $350 billion for the depleted Paycheck Protection Program (PPP), according to a summary of the legislation. Click here to see the full bill language. Separately, the bill increases the authorization level for the program by $310 billion.

Specifics:

  • $310 billion unrestricted for PPP
  • $60 billion in PPP set aside for smaller institutions (banks and credit unions)
    • $30 billion for assets less than $10 billion
    • $30 billion for assets between $10 billion and $50 billion
  • $50 billion for EIDL loans
  • $10 billion for EIDL Advance grants 
  • $2.1 billion for SBA administrative expenses

Health

  • $75B for hospitals (same language as PHSSEF from CARES)
  • $25B for testing [$11B of this will be distributed to states; the rest will go to CDC, BARDA, FQHC, NIH, NCI (they are doing the serology work), and others for research, development, and deployment of testing.]

This is great news for DMEPOS suppliers as it means additional funding availabilities. We’ve heard from many of you that have not received PPP funding from your bank. If you haven’t received any PPP dollars yet, it is recommended that you reach out to your credit union or bank this week to ensure you are first in line to receive these dollars. 

From Our Experts

Customization, Communication, and Clinical Strength: The Indie Edge in Complex Rehab thumbnail Customization, Communication, and Clinical Strength: The Indie Edge in Complex Rehab Independent complex rehab providers say they are differentiating themselves with product customization and referral and patient engagement. The Rising Cost of Doing Business in the Mobility and Complex Rehab Technology Industry thumbnail The Rising Cost of Doing Business in the Mobility and Complex Rehab Technology Industry This article delves into concerns of rising costs in the mobility and complex rehab technology (CRT) industry and explores potential strategies to mitigate their impact. Empowering Patients and Caregivers: Advocacy and Education thumbnail Empowering Patients and Caregivers: Advocacy and Education Whether it's a safety bed, mobility aid, or a respiratory device, healthcare providers' roles extend beyond equipment delivery—we are educators, advocates, and allies. Staffing Ratios and Compensation Insights for U.S. Rehab Members and CRT Dealers thumbnail Staffing Ratios and Compensation Insights for U.S. Rehab Members and CRT Dealers This report provides insights into team structures and pay for key roles like ATPs, service technicians, and billing personnel. Marketing: Embrace the Happy Customer thumbnail Marketing: Embrace the Happy Customer In today's hyper-connected world, customer satisfaction isn't just a metric—it's a marketing engine. A Letter From the President: July 2025 thumbnail A Letter From the President: July 2025 From evolving reimbursement models to the complexities of competitive bidding, the landscape continues to shift beneath our feet, but VGM is here for you. How the June 2025 MedPAC Report Shapes the Future of HME thumbnail How the June 2025 MedPAC Report Shapes the Future of HME The June 2025 Report to Congress from the Medicare Payment Advisory Commission (MedPAC) offers critical insights into the evolving landscape of Medicare services. While the report does not focus exclusively on home medical equipment (HME) or durable medical equipment (DME), several areas touch on themes that are highly relevant to the industry's future—particularly around home health care, Medicare Advantage (MA), and supplemental benefits. Navigating the New CMS Landscape with the HMV and RAD Decision Memo for COPD thumbnail Navigating the New CMS Landscape with the HMV and RAD Decision Memo for COPD Ronda Buhrmester, Sr. Director of Payer Relations and Reimbursement, shares insights on the newly finalized National Coverage Determination (NCD) for home mechanical ventilation (HMV) and respiratory assist devices (RAD).